Your browser doesn't support javascript.
loading
Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 950-956, 2014.
Artigo em Chinês | WPRIM | ID: wpr-302367
ABSTRACT
This study was aimed to investigate the clinical characteristics of acute myeloid leukemia (AML) with t (8;21) (q22;q22) and loss of Y chromosomes. Clinical data of 267 cases of AML were collected from January 2010 to June 2013. Among 267 AML, there were 13 cases with t (8;21) (q22;q22) and loss of Y chromosomes. The clinical data including clinical indicators, treatment protocols, curative effect and prognosis were analyzed retrospectively. The results showed that after normalized chemotherapy, there were 4 patients with complete remission at the first cycle of treatment, 4 patients with complete remission at the second cycle, 4 patients with complete remission at the third cycle, but one patient without complete remission after 4 cycles. There were 6 patients who did not relapse during consolidation and intensive therapy. Among these 6 patients, 4 cases accepted chemotherapy combined with transplantation, other 2 cases accepted chemotherapy. In the remainder 6 patients, 4 cases relapsed once, one cases relapsed twice, 1 cases relapsed for three times. Moreover, 2 cases who accepted the chemotherapy and auto-hematopoietic stem cell trans-plantation, were diagnosed as relapse, after accepted allo-hematopoietic stem cell transplantation, currently are in disease-free status. In follow-up period, the relapse-free survival (RFS) time was 4.67 ± 3.45 months in chemotherapy group, the RFS time is 34.17 ± 21.37 months in chemotherapy and transplantation group. The chemotherapy combined with transplantation extended the RFS time (P < 0.05). It is concluded that the NCCN guide indicates that AML with t (8;21) ( q22;q22) showed a good prognosis. but the clinical course of treatment confirmed that the prognosis of AML patients with t (8;21) (q22;q22) and loss Y chromosomes is poor, including uneasy remission and easy relapse, for improving the prognosis of these patients, the hematopoietic stem cell transplantation should be recommended.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Terapêutica / Translocação Genética / Cromossomos Humanos Par 8 / Cromossomos Humanos Par 21 / Indução de Remissão / Leucemia Mieloide Aguda / Estudos Retrospectivos / Deleção Cromossômica / Cromossomos Humanos Y Tipo de estudo: Guia de Prática Clínica / Estudo observacional / Estudo prognóstico Limite: Adolescente / Adulto / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2014 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Terapêutica / Translocação Genética / Cromossomos Humanos Par 8 / Cromossomos Humanos Par 21 / Indução de Remissão / Leucemia Mieloide Aguda / Estudos Retrospectivos / Deleção Cromossômica / Cromossomos Humanos Y Tipo de estudo: Guia de Prática Clínica / Estudo observacional / Estudo prognóstico Limite: Adolescente / Adulto / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2014 Tipo de documento: Artigo